Drug intelligence / Profile preview

dactolisib + trastuzumab

Development stage: Unknown
Lead developer: Novartis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of dactolisib (BEZ235), an oral dual inhibitor of class I PI3K and mTOR complexes 1 and 2, and trastuzumab, a monoclonal antibody targeting HER2. This combination is primarily studied for HER2-positive advanced breast cancer, particularly in patients who have developed resistance to trastuzumab alone. The combination targets both the PI3K/mTOR pathway and the HER2 receptor to overcome resistance mechanisms.

Brand names: HerceptinHerzumaKanjintiOgivriOntruzantTrazimeraHercessi
Other names: NVP-BEZ235NVP-BEZ-235NVP-BEZ 235

Targets

mTOR (Mammalian target of rapamycin kinase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)

Beyond the preview

Go deeper on dactolisib + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dactolisib + trastuzumab.

Explore the full profile